Elaine Ullian Sells 18,236 Shares of Hologic Inc. (HOLX) Stock
Hologic Inc. (NASDAQ:HOLX) Director Elaine Ullian sold 18,236 shares of the business’s stock in a transaction dated Monday, October 10th. The stock was sold at an average price of $39.88, for a total transaction of $727,251.68. Following the sale, the director now directly owns 42,898 shares of the company’s stock, valued at approximately $1,710,772.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Hologic Inc. (NASDAQ:HOLX) traded up 0.31% during midday trading on Wednesday, reaching $38.81. 1,368,877 shares of the company traded hands. Hologic Inc. has a 12 month low of $31.84 and a 12 month high of $41.66. The company’s 50 day moving average is $38.49 and its 200-day moving average is $36.32. The stock has a market capitalization of $10.77 billion, a price-to-earnings ratio of 42.79 and a beta of 1.00.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, July 27th. The company reported $0.51 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.03. The business earned $717.40 million during the quarter, compared to the consensus estimate of $703.66 million. Hologic had a net margin of 9.39% and a return on equity of 26.25%. The company’s quarterly revenue was up 3.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.43 earnings per share. Equities research analysts forecast that Hologic Inc. will post $1.94 earnings per share for the current fiscal year.
HOLX has been the topic of a number of recent research reports. Bank of America Corp. restated a “buy” rating on shares of Hologic in a research report on Wednesday, June 22nd. Leerink Swann restated a “buy” rating and set a $46.00 price target on shares of Hologic in a research report on Thursday, July 28th. Canaccord Genuity set a $45.00 price target on shares of Hologic and gave the stock a “buy” rating in a research report on Thursday, July 28th. Jefferies Group boosted their price target on shares of Hologic from $42.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday, July 28th. Finally, RBC Capital Markets restated a “sector perform” rating and set a $39.00 price target (up from $37.00) on shares of Hologic in a research report on Monday, August 1st. Six analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $42.71.
Large investors have recently modified their holdings of the company. HBK Investments L P increased its stake in shares of Hologic by 140.0% in the first quarter. HBK Investments L P now owns 433,900 shares of the company’s stock worth $14,970,000 after buying an additional 253,100 shares during the period. Hancock Holding Co. increased its stake in shares of Hologic by 2.2% in the first quarter. Hancock Holding Co. now owns 46,261 shares of the company’s stock worth $1,596,000 after buying an additional 977 shares during the period. Bogle Investment Management L P DE increased its stake in shares of Hologic by 747.3% in the first quarter. Bogle Investment Management L P DE now owns 339,755 shares of the company’s stock worth $11,721,000 after buying an additional 299,655 shares during the period. Geode Capital Management LLC increased its stake in shares of Hologic by 54.3% in the first quarter. Geode Capital Management LLC now owns 2,328,326 shares of the company’s stock worth $80,187,000 after buying an additional 819,646 shares during the period. Finally, Fairpointe Capital LLC increased its stake in shares of Hologic by 40.3% in the first quarter. Fairpointe Capital LLC now owns 20,900 shares of the company’s stock worth $721,000 after buying an additional 6,000 shares during the period. Institutional investors and hedge funds own 94.51% of the company’s stock.
Hologic Company Profile
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.